LV12187B - INSULATED HYDROXYKALKYL CHINOLINE LINES CARBON ACID - Google Patents
INSULATED HYDROXYKALKYL CHINOLINE LINES CARBON ACID Download PDFInfo
- Publication number
- LV12187B LV12187B LVP-98-153A LV980153A LV12187B LV 12187 B LV12187 B LV 12187B LV 980153 A LV980153 A LV 980153A LV 12187 B LV12187 B LV 12187B
- Authority
- LV
- Latvia
- Prior art keywords
- cooh
- compound
- formula
- vvas
- chet
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59688790A | 1990-10-12 | 1990-10-12 | |
US74188891A | 1991-08-08 | 1991-08-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
LV12187A LV12187A (lv) | 1998-12-20 |
LV12187B true LV12187B (en) | 1999-02-20 |
Family
ID=27082671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-98-153A LV12187B (en) | 1990-10-12 | 1998-07-23 | INSULATED HYDROXYKALKYL CHINOLINE LINES CARBON ACID |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0480717B1 (fr) |
JP (1) | JP2501385B2 (fr) |
KR (1) | KR100227716B1 (fr) |
CN (1) | CN1046711C (fr) |
AT (1) | ATE165088T1 (fr) |
CA (1) | CA2053209C (fr) |
CY (1) | CY2094B1 (fr) |
CZ (1) | CZ281274B6 (fr) |
DE (2) | DE19875039I2 (fr) |
DK (1) | DK0480717T3 (fr) |
ES (1) | ES2114882T3 (fr) |
FI (2) | FI104897B (fr) |
HK (1) | HK1027473A1 (fr) |
HR (1) | HRP930751B1 (fr) |
HU (2) | HU222344B1 (fr) |
IE (1) | IE913609A1 (fr) |
IL (3) | IL99726A (fr) |
LU (1) | LU90284I2 (fr) |
LV (1) | LV12187B (fr) |
MX (1) | MX9101551A (fr) |
NL (1) | NL990009I2 (fr) |
NO (1) | NO914004D0 (fr) |
NZ (1) | NZ240194A (fr) |
PT (1) | PT99213B (fr) |
SI (1) | SI9111647B (fr) |
SK (1) | SK279944B6 (fr) |
YU (1) | YU48742B (fr) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270324A (en) * | 1992-04-10 | 1993-12-14 | Merck Frosst Canada, Inc. | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists |
US5472964A (en) * | 1992-12-22 | 1995-12-05 | Merck Frosst Canada, Inc. | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists |
CA2111372C (fr) * | 1992-12-22 | 2007-01-16 | Robert N. Young | Acides heterocycliques diaryliques condenses en 5,6, antagonistes de la leucotriene |
US5438141A (en) * | 1993-05-21 | 1995-08-01 | Merck Frosst Canada, Inc. | Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists |
ES2080656B1 (es) * | 1993-07-19 | 1996-10-16 | Merck Frosst Canada Inc | Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno. |
CA2130723C (fr) * | 1993-09-03 | 2006-01-31 | Wilhelm Quittmann | Methode pour l'obtention de derives de l'acide y-mercaptocarboxylique |
DE4339724C1 (de) * | 1993-11-22 | 1995-01-19 | Siemens Ag | Gasarmatur |
TW416948B (en) * | 1993-12-28 | 2001-01-01 | Merck & Co Inc | Process for the preparation of leukotriene antagonists |
CA2145735A1 (fr) * | 1994-04-21 | 1995-10-22 | Paul Hanselmann | Methode de preparation de 5-oxaspiro[2.4]heptan-6-one et nouveaux produits intermediaires intervenant dans le processus |
US5523477A (en) * | 1995-01-23 | 1996-06-04 | Merck & Co., Inc. | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid |
US5750539A (en) * | 1995-06-07 | 1998-05-12 | Merck Frosst Canada | Heteroaryl diol acids as leukotriene antagonists |
US5714488A (en) * | 1995-10-03 | 1998-02-03 | Abbott Laboratories | Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis |
US5668150A (en) * | 1996-07-26 | 1997-09-16 | Abbott Laboratories | Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
FR2751969B1 (fr) * | 1996-08-01 | 1998-12-04 | Centre Nat Rech Scient | Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
US6221880B1 (en) | 1998-10-09 | 2001-04-24 | Schering Corporation | Composition and method for treating allergic diseases |
IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
CA2371048C (fr) | 2002-02-06 | 2011-01-04 | Delmar Chemicals Inc. | Procede de preparation d'acide 1-(mercaptomethyl)cyclopropylacetique |
AU2003244427A1 (en) * | 2002-02-06 | 2003-09-02 | Delmar Chemicals Inc. | Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid |
WO2003066598A1 (fr) * | 2002-02-07 | 2003-08-14 | Dr. Reddy's Laboratories Ltd. | Nouvelles formes amorphes anhydres de sel de sodium de montelukast |
ATE540926T1 (de) | 2003-06-06 | 2012-01-15 | Morepen Lab Ltd | Verbessertes verfahren zur herstellung von montelukastsäure natriumsalz in amorpher form |
IL174758A (en) | 2003-10-10 | 2012-09-24 | Synthon Bv | Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament |
US20070225325A1 (en) * | 2004-01-28 | 2007-09-27 | Pliva-Istrazivanje I Razvoj D.O.O. | Solid Forms of Montelukast Acid |
JP2007518826A (ja) * | 2004-01-30 | 2007-07-12 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカスト遊離酸多形体 |
EP1760077A1 (fr) * | 2004-01-30 | 2007-03-07 | Teva Pharmaceutical Industries Ltd. | Formes polymorphes du l'acide libre montelukast |
US7544805B2 (en) | 2004-02-03 | 2009-06-09 | Chemagis Ltd. | Stable amorphous forms of montelukast sodium |
WO2005105751A1 (fr) * | 2004-04-21 | 2005-11-10 | Teva Pharmaceutical Industries Ltd. | Procedes de preparation de sodium montelukast |
US7501517B2 (en) | 2004-04-30 | 2009-03-10 | Synthon Ip, Inc. | Process for making montelukast and intermediates therefor |
US7829716B2 (en) | 2004-04-30 | 2010-11-09 | Synthon Pharmaceuticals, Inc. | Process for making montelukast and intermediates therefor |
DE602004031678D1 (de) * | 2004-07-19 | 2011-04-14 | Matrix Lab Ltd | Verfahren zur herstellung von montelukast und salzen davon |
US7858793B2 (en) | 2004-07-19 | 2010-12-28 | Chava Satyanarayana | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates |
CA2574362A1 (fr) * | 2004-07-23 | 2006-01-26 | Pliva-Istrazivanje I Razvoj D.O.O. | Nouvelle forme de derive de benzenesulfonamide |
WO2006021974A1 (fr) * | 2004-08-23 | 2006-03-02 | Morepen Laboratories Limited | Procede pour synthetiser un diol (viii), intermediaire du sodium de montelukast |
PL205637B1 (pl) * | 2004-10-22 | 2010-05-31 | Inst Farmaceutyczny | Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli |
EP1817289A1 (fr) * | 2004-11-30 | 2007-08-15 | Medichem, S.A. | Nouveau procede de preparation d'un antagoniste de leucotriene |
WO2006131782A1 (fr) * | 2005-06-07 | 2006-12-14 | Glade Organics Private Limited | Procede de preparation de methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl)benzoate |
KR100899585B1 (ko) | 2005-07-05 | 2009-05-27 | 테바 파마슈티컬 인더스트리즈 리미티드 | 몬테루카스트의 정제 |
EP1948612A2 (fr) * | 2005-11-16 | 2008-07-30 | Teva Pharmaceutical Industries Ltd | Procede de sechage de montelukast sodique par distillation azeotropique du solvant |
AR057908A1 (es) | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar montelukast e intermediarios del mismo |
EP1968943B1 (fr) | 2005-12-13 | 2013-01-23 | MSN Laboratories Limited | Procede ameliore de preparation de montelukast et de ses sels pharmaceutiquement acceptables |
WO2007088545A2 (fr) | 2006-02-02 | 2007-08-09 | Chemagis Ltd. | Nouveau procédé pour la préparation de l'acide 1-[(mercaptométhyl)cyclopropane]acétique, un intermédiaire utile dans la préparation de montelukaste et des ses sels |
WO2007096889A2 (fr) | 2006-02-27 | 2007-08-30 | Chemagis Ltd. | Procede de preparation de montelukast et de ses sels |
EP2004609A2 (fr) * | 2006-03-06 | 2008-12-24 | Farmaprojects, S.A. | Procédé de préparation d'un antagoniste des leucotriènes |
CN101432267A (zh) | 2006-03-17 | 2009-05-13 | 斯索恩有限公司 | 孟鲁司特金刚烷胺盐 |
ATE524444T1 (de) | 2006-04-12 | 2011-09-15 | Glade Organics Private Ltd | Verbessertes verfahren zur herstellung von montelukast-natrium |
US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
GB0614485D0 (en) * | 2006-07-21 | 2006-09-27 | Pliva Istrazivanje I Razvoj D | Process |
EP1886998A1 (fr) | 2006-08-09 | 2008-02-13 | Esteve Quimica, S.A. | Procédés de purification du montelukast et ses sels d'amine |
GB0618703D0 (en) * | 2006-09-22 | 2006-11-01 | Almac Sciences Ltd | Synthesis of leikotriene compounds |
US7700776B2 (en) | 2006-10-24 | 2010-04-20 | Formosa Laboratories, Inc. | Compounds and preparation for montelukast sodium |
US8115004B2 (en) | 2006-11-20 | 2012-02-14 | Msn Laboratories Limited | Process for pure montelukast sodium through pure intermediates as well as amine salts |
US7271268B1 (en) | 2006-12-22 | 2007-09-18 | Formosa Laboratories Inc. | Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives |
EP1958936A1 (fr) * | 2007-02-14 | 2008-08-20 | Inke, S.A. | Procédé pour l'obtention de montelukast |
EP1988079A1 (fr) * | 2007-04-25 | 2008-11-05 | Lonza Ag | Processus de préparation d'alcools éthénylphényl actifs optiquement |
PL205444B1 (pl) | 2007-05-02 | 2010-04-30 | Zak & Lstrok Ady Farmaceutyczn | Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego |
ES2320077B1 (es) | 2007-07-31 | 2010-02-26 | Moehs Iberica, S.L. | Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo. |
KR101072896B1 (ko) | 2007-10-09 | 2011-10-17 | 한미홀딩스 주식회사 | 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법 |
EP2053043A1 (fr) | 2007-10-26 | 2009-04-29 | Inke, S.A. | Sel cristallin de montelukast |
DE102007061630B4 (de) | 2007-12-20 | 2013-07-04 | Formosa Laboratories, Inc. | Neue Verbindungen und Herstellung von Montelukast-Natrium |
CN101817818B (zh) * | 2008-03-06 | 2011-10-26 | 台耀化学股份有限公司 | 一种用于制备孟鲁司特钠的化合物 |
EP2288595B1 (fr) | 2008-05-26 | 2016-11-02 | Laurus Labs Private Limited | Procédé amélioré de préparation de montélukast et de ses sels |
TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
KR101123292B1 (ko) * | 2008-09-26 | 2012-03-19 | 주식회사 엘지생명과학 | 몬테루카스트 나트륨염의 제조방법 |
WO2010064109A2 (fr) | 2008-12-02 | 2010-06-10 | Mayuka Labs Private Limited | Procédé de préparation amélioré de montélukast sodique et ses intermédiaires |
WO2010107404A1 (fr) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Combinaisons pharmaceutiques stables |
US20120171126A1 (en) | 2009-06-16 | 2012-07-05 | Purakkattle Biju J | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF |
WO2011004298A1 (fr) | 2009-07-09 | 2011-01-13 | Alembic Limited | Montélukast à l'état hexaméthylène-diamine, et son utilisation pour l'élaboration de montélukast sodique |
EP2287154A1 (fr) | 2009-07-14 | 2011-02-23 | KRKA, D.D., Novo Mesto | Synthèse efficace pour la préparation de montelukast |
CN101638381B (zh) | 2009-09-02 | 2012-08-29 | 鲁南制药集团股份有限公司 | 孟鲁司特钠中间体的合成方法 |
EP2486015A1 (fr) * | 2009-10-09 | 2012-08-15 | DSM IP Assets B.V. | Synthèse d'un intermédiaire optiquement actif pour la préparation de montélukast |
AU2009357276A1 (en) | 2009-12-23 | 2012-08-09 | Pharmathen S.A. | Improved process for the preparation of Montelukast and salts thereof |
WO2011121091A1 (fr) | 2010-03-31 | 2011-10-06 | Krka, D.D., Novo Mesto | Synthèse efficace pour la préparation de montélukast et nouvelle forme cristalline d'intermédiaires dans celle-ci |
KR100990046B1 (ko) * | 2010-07-30 | 2010-10-26 | 동국제약 주식회사 | 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법 |
HUP1000425A2 (en) | 2010-08-11 | 2012-03-28 | Richter Gedeon Nyrt | Process for the production of montelukast sodium |
TR201009394A2 (tr) | 2010-11-11 | 2012-06-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş montelukast formülasyonları. |
TR201009398A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Fiziksel özellikleri geliştirilmiş tablet formülasyonları |
US8471030B2 (en) | 2010-12-06 | 2013-06-25 | Orochem Technologies Inc. | Purification of montelukast using simulated moving bed |
EP2502910A1 (fr) | 2011-03-15 | 2012-09-26 | Laboratorios Lesvi, S.L. | Sel de camphre sulfonique d'un intermédiaire clef du Montélukast |
CN102690229B (zh) * | 2011-03-23 | 2016-06-08 | 上海相辉医药科技有限公司 | 一种孟鲁司特钠的合成及其制备中间体 |
EP2736885B1 (fr) * | 2011-07-26 | 2020-03-25 | Sun Pharma Advanced Research Company Ltd | Antagonistes des cystéinyl leucotriènes |
WO2013077829A1 (fr) | 2011-11-21 | 2013-05-30 | Mahmut Bilgic | Granulés pharmaceutiques hydrosolubles |
WO2014118796A1 (fr) | 2013-01-31 | 2014-08-07 | Melody Healthcare Pvt. Ltd. | Procédé in situ pour la préparation de montélukast sodique hautement pur |
CN104109122B (zh) * | 2013-04-16 | 2017-03-29 | 浙江奥翔药业股份有限公司 | 用于合成孟鲁司特的中间体化合物及其制备方法 |
CN104370810B (zh) * | 2013-08-13 | 2016-10-05 | 天津汉瑞药业有限公司 | 孟鲁司特钠化合物 |
CN103554017B (zh) * | 2013-10-25 | 2014-12-17 | 河北序能生物技术有限公司 | 一种孟鲁司特钠手性中间体的制备方法 |
CN103936671B (zh) * | 2014-05-06 | 2015-10-28 | 启东东岳药业有限公司 | 孟鲁司特钠中间体的制备方法 |
CN105294556A (zh) * | 2014-06-06 | 2016-02-03 | 上海迪赛诺化学制药有限公司 | 一种制备孟鲁司特酸的方法 |
CN105085391B (zh) | 2015-06-10 | 2017-08-22 | 广东默泰同创医药科技有限公司 | 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用 |
CN108273039B (zh) * | 2015-12-16 | 2021-04-30 | 新乡医学院第一附属医院 | 一种治疗溶血性贫血的药物组合物及其应用 |
CN108530355B (zh) * | 2018-06-08 | 2019-09-10 | 福州华博立乐新材料科技有限公司 | 一种3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的合成方法 |
CN108435257A (zh) * | 2018-06-08 | 2018-08-24 | 福州华博立乐新材料科技有限公司 | 一种用于合成3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的催化剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK282986A (da) * | 1985-06-18 | 1987-02-24 | Merck Frosst Canada Inc | Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse |
US4851409A (en) * | 1986-02-14 | 1989-07-25 | Merck Frosst Canada Inc. | 2-substituted quinoline dioic acids and pharmaceutical compositions |
IE59889B1 (en) * | 1986-02-14 | 1994-04-20 | Merck Frosst Canada Inc | 2-substituted quinoline dioic acids |
JPS62258362A (ja) * | 1986-05-02 | 1987-11-10 | Terumo Corp | アミド誘導体およびこれを含有する5−リポキシゲナ−ゼ作用阻害剤 |
EP0271287A3 (fr) * | 1986-12-11 | 1990-06-13 | Merck Frosst Canada Inc. | Acides quinoléine dicarboxyliques et leurs amides |
EP0318093A3 (fr) * | 1987-11-25 | 1990-12-05 | Merck Frosst Canada Inc. | Acides dicarboxyliques des diaryl quinoléines et leur utilisation comme médicaments |
NZ233752A (en) * | 1989-05-24 | 1993-05-26 | Merck Frosst Canada Inc | Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof |
WO1990015801A1 (fr) * | 1989-06-22 | 1990-12-27 | Pfizer Inc. | Sulfamides substitues et composes apparentes dans le traitement de l'asthme, de l'arthrite et des maladies apparentees |
-
1991
- 1991-10-10 CA CA002053209A patent/CA2053209C/fr not_active Expired - Lifetime
- 1991-10-10 DK DK91309306T patent/DK0480717T3/da active
- 1991-10-10 DE DE1998175039 patent/DE19875039I2/de active Active
- 1991-10-10 DE DE69129257T patent/DE69129257T2/de not_active Expired - Lifetime
- 1991-10-10 EP EP91309306A patent/EP0480717B1/fr not_active Expired - Lifetime
- 1991-10-10 ES ES91309306T patent/ES2114882T3/es not_active Expired - Lifetime
- 1991-10-10 HU HU9103217A patent/HU222344B1/hu active IP Right Grant
- 1991-10-10 AT AT91309306T patent/ATE165088T1/de active
- 1991-10-11 YU YU164791A patent/YU48742B/sh unknown
- 1991-10-11 NZ NZ240194A patent/NZ240194A/en not_active IP Right Cessation
- 1991-10-11 NO NO914004A patent/NO914004D0/no unknown
- 1991-10-11 SI SI9111647A patent/SI9111647B/sl unknown
- 1991-10-11 MX MX9101551A patent/MX9101551A/es unknown
- 1991-10-11 FI FI914796A patent/FI104897B/fi not_active IP Right Cessation
- 1991-10-11 SK SK3095-91A patent/SK279944B6/sk not_active IP Right Cessation
- 1991-10-11 PT PT99213A patent/PT99213B/pt not_active IP Right Cessation
- 1991-10-11 CZ CS913095A patent/CZ281274B6/cs not_active IP Right Cessation
- 1991-10-11 CN CN91110816A patent/CN1046711C/zh not_active Expired - Lifetime
- 1991-10-12 KR KR1019910017953A patent/KR100227716B1/ko not_active IP Right Cessation
- 1991-10-13 IL IL99726A patent/IL99726A/en not_active IP Right Cessation
- 1991-10-13 IL IL11714791A patent/IL117147A/xx not_active IP Right Cessation
- 1991-10-13 IL IL11714796A patent/IL117147A0/xx unknown
- 1991-10-14 JP JP3331110A patent/JP2501385B2/ja not_active Expired - Lifetime
- 1991-10-16 IE IE360991A patent/IE913609A1/en active Protection Beyond IP Right Term
-
1993
- 1993-04-02 HR HR930751A patent/HRP930751B1/xx not_active IP Right Cessation
-
1995
- 1995-06-09 HU HU95P/P00178P patent/HU211294A9/hu unknown
-
1998
- 1998-07-14 HK HK98109133A patent/HK1027473A1/xx not_active IP Right Cessation
- 1998-07-17 CY CY9800016A patent/CY2094B1/xx unknown
- 1998-07-23 LV LVP-98-153A patent/LV12187B/en unknown
- 1998-09-02 LU LU90284C patent/LU90284I2/fr unknown
-
1999
- 1999-04-01 NL NL990009C patent/NL990009I2/nl unknown
-
2000
- 2000-02-07 FI FI20000250A patent/FI20000250A/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV12187B (en) | INSULATED HYDROXYKALKYL CHINOLINE LINES CARBON ACID | |
US5565473A (en) | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | |
US5270324A (en) | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | |
CA2053216C (fr) | Derives acides d'hyroxyalkylquinoline saturee comme antagonistes des leucotrienes | |
CA1333714C (fr) | Acides alcanoiques derives d'ethers quinoliniques utiles comme inhibiteurs de la biosynthese de la leucotriene | |
US5856322A (en) | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | |
AU648385B2 (en) | Quinoline-containing ketoacids as leukotriene antagonists | |
US5266568A (en) | Hydroxyalkylquinoline ether acids as leukotriene antagonists | |
US5472964A (en) | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists | |
US5232916A (en) | Quinoline ether alkanoic acids | |
CA2053208C (fr) | Derives acides d'oxydes d'hydroxyalkylquinoline comme antagonistes des leucotrienes | |
US5102881A (en) | Quinoline ether alkanoic acids | |
US5212180A (en) | Quinoline-containing ketoacids as leukotriene antagonists | |
NO180086B (no) | Umettede hydroxyalkylkinolinsyrer som leukotrienantagonister |